Anfield Capital Management’s Aethlon Medical AEMD Stock Holding History

Anfield Capital Management’s Portfolio AEMD Stock Details AEMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$20	–	456
2024 Q2	$20	Buy	+1	New	+$79	﹤0.01%	399

Other funds holding AEMD

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Anfield Capital Management's AEMD Position: Q3 2024 in Review

Anfield Capital Management sold out of Aethlon Medical (AEMD) in Q3 2024, closing a stake of 1 share — an estimated $20 sold.

Anfield Capital Management first reported a position in AEMD in Q2 2024 and held it in 1 quarter. The position peaked at $20 in Q2 2024. 15 funds tracked by Wall St. Rank hold AEMD as of Q3 2024.

Anfield Capital Management reported no remaining Aethlon Medical position as of Q3 2024 after selling out during the quarter.
Anfield Capital Management sold 1 Aethlon Medical share in Q3 2024, an estimated $20.
Anfield Capital Management first reported a position in Aethlon Medical in Q2 2024 and held it in 1 quarter.
Anfield Capital Management's Aethlon Medical position peaked at $20 in Q2 2024.
15 funds tracked by Wall St. Rank held Aethlon Medical as of Q3 2024.

Based on Anfield Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.